Clinical trial
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida…
NCT00002041 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00002041 |
|---|---|
| Title | Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients |
| Official title | Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Candidiasis, Esophageal, HIV Infections |
| Intervention type | Drug |
| Interventions | Amphotericin B |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 2, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: